TICKERNOMICS Sign up
Last Update: 2023-12-23 06:03:02
Eliem Therapeutics Inc. ( ELYM ) https://www.eliemtx.com
2.62USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
-10.58%
ELYM
SPY
30.72%
ELYM
0.00%
SPY
112.82%
ELYM
0.00%
SPY
201.04%
ELYM
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
74.72
25.10
0.00
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-2.06
0.00
0.68
0.00
0.00
-0.53
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
3.86
-54.99
-27.12
0.00
Other Earnings and Cash Flow Stats:
Eliem Therapeutics Inc. ( ELYM ) Net Income TTM ($MM) is -41.70
Eliem Therapeutics Inc. ( ELYM ) Operating Income TTM ($MM) is -46.74
Eliem Therapeutics Inc. ( ELYM ) Owners' Earnings Annual ($MM) is 0.00
Eliem Therapeutics Inc. ( ELYM ) Current Price to Owners' Earnings ratio is 0.00
Eliem Therapeutics Inc. ( ELYM ) EBITDA TTM ($MM) is -47.33
Eliem Therapeutics Inc. ( ELYM ) EBITDA Margin is 0.00%
Capital Allocation:
Eliem Therapeutics Inc. ( ELYM ) has paid 0.00 dividends per share and bought back -0.735024 million shares in the past 12 months
Eliem Therapeutics Inc. ( ELYM ) has reduced its debt by 0.112 million USD in the last 12 months
Capital Structure:
Eliem Therapeutics Inc. ( ELYM ) Interest-bearing Debt ($MM) as of last quarter is 0
Eliem Therapeutics Inc. ( ELYM ) Annual Working Capital Investments ($MM) are 29
Eliem Therapeutics Inc. ( ELYM ) Book Value ($MM) as of last quarter is 109
Eliem Therapeutics Inc. ( ELYM ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Eliem Therapeutics Inc. ( ELYM ) has 57 million in cash on hand as of last quarter
Eliem Therapeutics Inc. ( ELYM ) has 2 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Eliem Therapeutics Inc. ( ELYM ) has 27 common shares outstanding as of last quarter
Eliem Therapeutics Inc. ( ELYM ) has 0 million USD of preferred stock value
Academic Scores:
Eliem Therapeutics Inc. ( ELYM ) Altman Z-Score is 12.94 as of last quarter
Eliem Therapeutics Inc. ( ELYM ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Eliem Therapeutics Inc. ( ELYM ) largest shareholder is State Street Corporation owning 19800 shares at 0.05 ($MM) value
(an insider) shares of Eliem Therapeutics Inc. ( ELYM ) for the amount of $ on
26.07% of Eliem Therapeutics Inc. ( ELYM ) is held by insiders, and 67.94% is held by institutions
Eliem Therapeutics Inc. ( ELYM ) went public on 2021-08-10
Other Eliem Therapeutics Inc. ( ELYM ) financial metrics:
FCF:-24.31
Unlevered Free Cash Flow:0.00
EPS:-0.59
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-14.46
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Eliem Therapeutics Inc. ( ELYM ) :
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial. The company was incorporated in 2018 and is headquartered in Redmond, Washington.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.